Owlet remains a buy despite flat stock performance, supported by strong Q2 results and ongoing business evolution. Q2 revenue hit a record $33.9M (up 29.9% YoY), with gross margin rebounding to 54% and subscription growth driving margin expansion. Management maintained 2026 guidance, forecasting $120M revenue (13.5% growth) and $8M EBITDA, with international and subscription segments as key growth drivers.
Owlet, Inc. offers the only FDA-approved wearable infant monitor, leveraging patents and data to build a subscription-based telehealth platform. OWLT's pivot to a recurring subscription model targets 1 million users, aiming for higher margins and revenue stability amid ongoing cash burn. Gross margin guidance was raised to 53-55%, with 2026 revenue reaffirmed at $118-$122 million, but near-term profitability remains elusive.
Owlet NYSE: OWLT reported record second-quarter revenue as growth in its connected baby-monitoring products, international markets and subscription business helped offset promotional pressure in the category.
| Health Care Technology Industry | Healthcare Sector | Kurt Workman CEO | NYSE Exchange | 69120X206 CUSIP |
| US Country | 111 Employees | - Last Dividend | 10 Jul 2023 Last Split | 5 Nov 2020 IPO Date |
Owlet, Inc. is a company dedicated to pioneering digital parenting solutions both in the United States and around the globe. With a focus on providing real-time data and insights to parents, Owlet aims to ease the challenges of parenting through innovative technology. The company's mission revolves around enhancing the safety and well-being of infants by offering a suite of products that monitor vital signs and sleep patterns. Since its inception in 2012, Owlet has established its headquarters in Lehi, Utah, and has become a key player in the realm of infant health monitoring technology.
Owlet’s extensive range of products and services is designed to deliver peace of mind to parents by keeping them informed about their baby’s health and wellness.